Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Suppression of invasion and peritoneal carcinomatosis of ovarian cancer cells by overexpression of AP-2α

Oncogene volume 23, pages 5496–5504 (2004)Cite this article

Abstract

A previous report demonstrated that AP-2α favors the survival of ovarian cancer patients by clinical findings. However, the functional roles of AP-2α in human ovarian cancers have not been determined. To clarify the roles, we overexpressed AP-2α in SKOV3 human ovarian cancer cells, which originally possess little AP-2α. AP-2α overexpression changed cell morphology from spindle to epithelioid type and suppressed cell proliferation and invasion, which would be partially correlated with decreased phosphorylation levels of the erbB2, Akt and ERK pathways, increased E-cadherin and reduced pro-matrix metalloproteinase-2 levels. Moreover, nude mice intraperitoneally injected with AP-2α-overexpressing cells survived longer than those with neo-transfected cells. The present data represent the first direct evidence that AP-2α plays a tumor suppressive role in ovarian cancer.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8

Similar content being viewed by others

References

  • Agus DB, Bunn Jr PA, Franklin W, Garcia M and Ozols RF . (2000). Semin. Oncol., 27, 53–63 (discussion 92–100).

  • Anttila MA, Kellokoski JK, Moisio KI, Mitchell PJ, Saarikoski S, Syrjanen K and Kosma VM . (2000). Br. J. Cancer, 82, 1974–1983.

  • Auman HJ, Nottoli T, Lakiza O, Winger Q, Donaldson S and Williams T . (2002). Development, 129, 2733–2747.

  • Bacus SS, Zelnick CR, Plowman G and Yarden Y . (1994). Am. J. Clin. Pathol., 102, S13–24.

  • Bar-Eli M . (1997). J. Cell Physiol., 173, 275–278.

  • Bar-Eli M . (2001). Pigment Cell Res., 14, 78–85.

  • Bosher JM, Totty NF, Hsuan JJ, Williams T and Hurst HC . (1996). Oncogene, 13, 1701–1707.

  • Buettner R, Kannan P, Imhof A, Bauer R, Yim SO, Glockshuber R, Van Dyke MW and Tainsky MA . (1993). Mol. Cell. Biol., 13, 4174–4185.

  • Cliby W, Ritland S, Hartmann L, Dodson M, Halling KC, Keeney G, Podratz KC and Jenkins RB . (1993). Cancer Res., 53, 2393–2398.

  • Daly RJ . (1999). Growth Factors, 16, 255–263.

  • Davidson B . (2001). Anal. Cell Pathol., 23, 107–128.

  • Egan SE and Weinberg RA . (1993). Nature, 365, 781–783.

  • Enomoto T, Inoue M, Perantoni AO, Terakawa N, Tanizawa O and Rice JM . (1990). Cancer Res., 50, 6139–6145.

  • Foulkes WD, Ragoussis J, Stamp GW, Allan GJ and Trowsdale J . (1993). Br. J. Cancer, 67, 551–559.

  • Gaubatz S, Imhof A, Dosch R, Werner O, Mitchell P, Buettner R and Eilers M . (1995). EMBO J., 14, 1508–1519.

  • Gaynor RB, Muchardt C, Xia YR, Klisak I, Mohandas T, Sparkes RS and Lusis AJ . (1991). Genomics, 10, 1100–1102.

  • Gershenwald JE, Sumner W, Calderone T, Wang Z, Huang S and Bar-Eli M . (2001). Oncogene, 20, 3363–3375.

  • Hayakawa A, Yokoyama I, Tajiri H, Okamoto T and Nakashima I . (1999). Cancer Lett., 140, 113–119.

  • Ho AT, Voura EB, Soloway PD, Watson KL and Khokha R . (2001). J. Biol. Chem., 276, 40215–40224.

  • Huang S, Jean D, Luca M, Tainsky MA and Bar-Eli M . (1998). EMBO J., 17, 4358–4369.

  • Jean D, Gershenwald JE, Huang S, Luca M, Hudson MJ, Tainsky MA and Bar-Eli M . (1998). J. Biol. Chem., 273, 16501–16508.

  • Kajiyama H, Kikkawa F, Suzuki T, Shibata K, Ino K and Mizutani S . (2002). Cancer Res., 62, 2753–2757.

  • Kavanaugh WM and Williams LT . (1994). Science, 266, 1862–1865.

  • Kikkawa F, Kojima M, Oguchi H, Maeda O, Ishikawa H, Tamakoshi K, Mizuno K, Kawai M, Suganuma N and Tomoda Y . (1993). Anticancer Res., 13, 891–896.

  • Kikkawa F, Matsuzawa K, Arii Y, Kawai M, Kobayashi I, Nakashima N and Mizutani S . (2000). Gynecol. Obstet. Invest., 50, 269–274.

  • Klapper LN, Kirschbaum MH, Sela M and Yarden Y . (2000). Adv. Cancer Res., 77, 25–79.

  • Levkowitz G, Klapper LN, Tzahar E, Freywald A, Sela M and Yarden Y . (1996). Oncogene, 12, 1117–1125.

  • Luo J, Lubaroff DM and Hendrix MJ . (1999). Cancer Res., 59, 3552–3556.

  • Luttrell DK, Lee A, Lansing TJ, Crosby RM, Jung KD, Willard D, Luther M, Rodriguez M, Berman J and Gilmer TM . (1994). Proc. Natl. Acad. Sci. USA, 91, 83–87.

  • McPherson LA, Loktev AV and Weigel RJ . (2002). J. Biol. Chem., 277, 45028–45033.

  • Mizuno K, Furuhashi Y, Misawa T, Iwata M, Kawai M, Kikkawa F, Kano T and Tomoda Y . (1992). Anticancer Res., 12, 21–25.

  • Mizutani S, Sumi S, Narita O and Tomoda Y . (1985). Nippon Sanka. Fujinka. Gakkai. Zasshi, 37, 769–775.

  • Moser M, Pscherer A, Roth C, Becker J, Mucher G, Zerres K, Dixkens C, Weis J, Guay-Woodford L, Buettner R and Fassler R . (1997). Genes Dev., 11, 1938–1948.

  • Nawrocki-Raby B, Gilles C, Polette M, Martinella-Catusse C, Bonnet N, Puchelle E, Foidart JM, Van Roy F and Birembaut P . (2003). Am. J. Pathol., 163, 653–661.

  • Olayioye MA, Graus-Porta D, Beerli RR, Rohrer J, Gay B and Hynes NE . (1998). Mol. Cell. Biol., 18, 5042–5051.

  • Orsulic S, Li Y, Soslow RA, Vitale-Cross LA, Gutkind JS and Varmus HE . (2002). Cancer Cell, 1, 53–62.

  • Qvist H, Sjostrom H and Noren O . (1998). Biol. Chem., 379, 75–81.

  • Schmalfeldt B, Prechtel D, Harting K, Spathe K, Rutke S, Konik E, Fridman R, Berger U, Schmitt M, Kuhn W and Lengyel E . (2001). Clin. Cancer Res., 7, 2396–2404.

  • Slamon DJ . (1987). N. Engl. J. Med., 317, 955–957.

  • Turner BC, Zhang J, Gumbs AA, Maher MG, Kaplan L, Carter D, Glazer PM, Hurst HC, Haffty BG and Williams T . (1998). Cancer Res., 58, 5466–5472.

  • Venkateswarlu S, Dawson DM, St Clair P, Gupta A, Willson JK and Brattain MG . (2002). Oncogene, 21, 78–86.

  • Vernimmen D, Gueders M, Pisvin S, Delvenne P and Winkler R . (2003). Br. J. Cancer, 89, 899–906.

  • Vikhanskaya F, Erba E, D’Incalci M and Broggini M . (1994). Nucleic Acids Res., 22, 1012–1017.

  • West-Mays JA, Sivak JM, Papagiotas SS, Kim J, Nottoli T, Williams T and Fini ME . (2003). Differentiation, 71, 206–216.

  • Williams T and Tjian R . (1991). Genes Dev., 5, 670–682.

  • Williamson JA, Bosher JM, Skinner A, Sheer D, Williams T and Hurst HC . (1996). Genomics, 35, 262–264.

  • Zhang J, Hagopian-Donaldson S, Serbedzija G, Elsemore J, Plehn-Dujowich D, McMahon AP, Flavell RA and Williams T . (1996). Nature, 381, 238–241.

  • Zhao F, Satoda M, Licht JD, Hayashizaki Y and Gelb BD . (2001). J. Biol. Chem., 276, 40755–40760.

  • Zhu CH and Domann FE . (2002). Breast Cancer Res. Treat., 71, 47–57.

Download references

Acknowledgements

This study was partly supported by Grants-in-Aid from the Ministry of Education, Culture, Sports, Science and Technology of Japan, from R01CA053475, and from the Ministry of Public Management, Home Affairs, Posts and Telecommunications of Japan for specific medical research (in collaboration with Nagoya Teishin Hospital).

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, Nagoya Graduate University School of Medicine, Tsurumai-cho 65, Showa-ku, Nagoya, 466-8550, Japan

    Seiji Sumigama, Tomomi Ito, Hiroaki Kajiyama, Kiyosumi Shibata, Fumitaka Kikkawa, Seiji Nomura & Shigehiko Mizutani

  2. Department of Public Health, Nagoya Graduate University School of Medicine, Tsurumai-cho 65, Showa-ku, Nagoya, 466-8550, Japan

    Koji Tamakoshi

  3. Department of Craniofacial Biology, University of Colorado Health Sciences, Denver, 80262, CO, USA

    Trevor Williams

  4. Program in Molecular Biology and Genetics, Karmanos Cancer Institute, Wayne State University, 110 East Warren Avenue, Detroit, 48201, MI, USA

    Michael A Tainsky

Authors
  1. Seiji Sumigama
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tomomi Ito
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hiroaki Kajiyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kiyosumi Shibata
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Koji Tamakoshi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Fumitaka Kikkawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Trevor Williams
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Michael A Tainsky
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Seiji Nomura
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Shigehiko Mizutani
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tomomi Ito.

Additional information

Supplementary Information accompanies the paper on Oncogene website (http://www.nature.com/onc)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sumigama, S., Ito, T., Kajiyama, H. et al. Suppression of invasion and peritoneal carcinomatosis of ovarian cancer cells by overexpression of AP-2α. Oncogene 23, 5496–5504 (2004). https://doi.org/10.1038/sj.onc.1207723

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1207723

Keywords

This article is cited by

Search

Advanced search

Quick links